216 unknown. 216 Phase 1, 99 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 216 | Unknown 216 |
| Phase 2 | 99 | Unknown 99 |
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma Autologous Tumor-infiltrating Lymphocytes - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | Beijing 302 Hospital | 20 | 2024-07-01 | 2024-08-13 |
| Safety of DNP007 in Healthy Subjects DNP007 - Liver Transplant Rejection, Liver Transplant; Complications | Phase 1 | Unknown | Seoul National University Hospital | 12 | 2024-06-10 | 2024-06-18 |
| Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis Esomeprazole, Placebo - Fatty Liver Disease, Steatohepatitis, Nonalcoholic | Phase 1 / Phase 2 | Unknown | Sadat City University | 46 | 2024-06-01 | 2024-05-22 |
| A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B TQA3038 injection/placebo, Nucleotide drugs Control group - Hepatitis B, Chronic | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 162 | 2024-06-01 | 2024-06-11 |
| Effect of 4 Weeks of Oral D. Piger on Safety, Pharmacokinetics and Ethanol Metabolism in Overweight Individuals (2023) D piger, Placebo - Obesity, Metabolic Syndrome | Phase 1 | Unknown | Max Nieuwdorp | 20 | 2024-05-01 | 2024-07-16 |
| Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma γδ T cells, Targeted drugs, PD-1 monoclonal antibody - Hepatocellular Carcinoma | Phase 1 | Unknown | Beijing 302 Hospital | 18 | 2024-04-26 | 2024-04-15 |
| Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies lenvatinib + anti-PD-1 antibodies, ablation - Hepatocellular Carcinoma | Phase 1 | Unknown | Hua Li | 70 | 2024-01-01 | 2024-07-24 |
| Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride ET-26 - Hepatic Insufficiency | Phase 1 | Unknown | Ahon Pharmaceutical Co., Ltd. | 24 | 2023-12-06 | 2023-12-20 |
| A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects TQA3038 injection, TQA3038 injection matching placebo - Chronic Hepatitis b | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 54 | 2023-11-30 | 2023-12-05 |
| Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for Injection - Primary Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | CNBG-Virogin Biotech (Shanghai) Ltd. | 36 | 2023-11-30 | 2023-11-15 |
| NWRD06 DNA Plasmid for HCC After Radical Resection 1mg NWRD06 administered by electroporation, 4mg NWRD06 administered by electroporation, 8mg NWRD06 administered by electroporation - Hepatocellular Carcinoma | Phase 1 | Unknown | Newish Technology (Beijing) Co., Ltd. | 9 | 2023-11-01 | 2023-10-18 |
| Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent PB101 - Solid Tumor, Adult, Solid Tumor | Phase 1 | Unknown | Panolos Bioscience | 30 | 2023-10-25 | 2024-02-23 |
| Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue GIP/GLP-1a - Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis | Phase 1 / Phase 2 | Unknown | Dr Adnan Agha | 30 | 2023-10-01 | 2024-01-12 |
| BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma BC3402 injection, Durvalumab injection - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | Biocity Biopharmaceutics Co., Ltd. | 83 | 2023-10-01 | 2023-11-01 |
| 3D Printed Models for Liver Surgery 3D Printed Model for preoperative planning - Liver Cancer | Phase 1 | Unknown | Zhejiang Cancer Hospital | 5 | 2023-09-15 | 2023-09-21 |
| To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 EU307 CAR-T Cell - Advanced Hepatocellular Carcinoma | Phase 1 | Unknown | Eutilex | 12 | 2023-08-24 | 2024-03-15 |
| To Evaluate the Clinical Study of CUD005 Injection in Patients With Cirrhosis Cell therapy - Cirrhosis, Liver | Phase 1 | Unknown | Anhui Provincial Hospital | 9 | 2023-08-09 | 2024-03-06 |
| Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects Test drug XT1061 capsules and placebo,Single dose group, Test drug XT1061 capsules and placebo，Multiple dosing group, Test drug XT1061 capsules and placebo，Food Impact Group - Chronic Hepatitis b | Phase 1 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 128 | 2023-07-18 | 2024-02-28 |
| A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 1 | Unknown | LG Chem | 42 | 2023-07-17 | 2023-07-19 |
| Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma adebrelimab, camrelizumab plus apatinib - Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 52 | 2023-07-01 | 2024-02-21 |
Showing 20 of 216. Sign in to see all of them.
Carcinoma, Hepatocellular (109) · Liver Neoplasms (26) · Liver Cirrhosis (23) · Colorectal Neoplasms (15) · Stomach Neoplasms (15) · Hepatitis B, Chronic (14) · Pancreatic Neoplasms (14) · Non-alcoholic Fatty Liver Disease (13) · Esophageal Neoplasms (8) · Breast Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (7) · End Stage Liver Disease (7) · Fibrosis (7) · Hepatitis C (7)
Digestive System Diseases (215) · Digestive System Neoplasms (126) · Neoplasms by Site (126) · Neoplasms (120) · Neoplasms by Histologic Type (113) · Neoplasms, Glandular and Epithelial (112) · Adenocarcinoma (109) · Carcinoma (109) · Liver Neoplasms (100) · Pathological Conditions, Signs and Symptoms (63) · Pathologic Processes (60) · Hepatitis (33) · Gastrointestinal Diseases (30) · Blood-Borne Infections (29)
Sorafenib (7) · lenvatinib (7) · apatinib (6) · camrelizumab (6) · Congresses as Topic (5) · sintilimab (5) · Immunotherapy, Adoptive (4) · tislelizumab (4) · Bevacizumab (3) · Fecal Microbiota Transplantation (3) · Nivolumab (3) · Radiotherapy (3) · peginterferon alfa-2a (3) · toripalimab (3) · Cyclophosphamide (2)
Beijing 302 Hospital (10) · Fudan University (5) · National Taiwan University Hospital (5) · Third Affiliated Hospital, Sun Yat-Sen University (5) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (4) · Peking Union Medical College Hospital (4) · Shanghai Zhongshan Hospital (4) · Air Force Military Medical University, China (3) · Cytheris SA (3) · Shanghai GeneChem Co., Ltd. (3) · Sun Yat-sen University (3) · Zhejiang University (3) · Assiut University (2) · Baermed (2) · Beijing Tsinghua Chang Gung Hospital (2)
China (115) · United States (20) · Taiwan (10) · France (7) · South Korea (5) · United Kingdom (5) · Egypt (3) · Italy (3) · Japan (3) · Singapore (3) · Switzerland (3) · Australia (2) · Bangladesh (2) · Brazil (2) · Canada (2)
Daiming Fan (3) · Fu-Sheng Wang, professor (2) · Junqi Niu, PHD (2) · Lin Yang, Ph.D. (2) · Mamun A Mahtab, MSc MD FACG (2) · Shen Feng, MD (2) · Yanhua Ding, MD (2) · Yi-Xin Zeng, Ph.D. (2) · Adnan Agha, FRCP (1) · Alejandro Soza, MD (1) · Anil Dhawan, Professor (1) · Antonio Bertoletti, MD (1) · Baburao Koneru, MD (1)
PMID 15623621, PMID 15868910, PMID 16951235, PMID 17903050, PMID 19192962, PMID 19455046, PMID 19638109, PMID 20149262, PMID 21277098, PMID 22461641, PMID 23134470, PMID 24668644, PMID 24876849, PMID 25747273, PMID 25788178, PMID 26006200, PMID 26228759, PMID 26871284, PMID 27010381, PMID 27756258, PMID 27766709, PMID 27780345, PMID 27781199, PMID 27793949, PMID 27916360, PMID 28054442, PMID 29864682, PMID 30348638, PMID 30863450, PMID 32357963, PMID 32425926, PMID 33123384, PMID 34155211, PMID 34850325, PMID 34965951, PMID 34998048, PMID 35404074, PMID 35491432, PMID 35853994, PMID 36089112, PMID 36441083, PMID 36505833, PMID 37060176, PMID 37067675, PMID 37104017, PMID 37215108, PMID 37981041, PMID 38114507, PMID 38808361, PMID 39358661
2009 (3), 2014 (1), 2015 (1), 2016 (1), 2017 (1), 2019 (1), M01RR000051 (1)